Close Menu

Memorial Sloan-Kettering

Under the Phenotypic Drug Discovery program, researchers from academia or biotech submit candidate compounds in specific therapeutic areas for Lilly to evaluate and profile. Participating organizations retain full IP rights to the compounds, but Lilly receives first rights to negotiate a broader collaboration or licensing agreement.

A group of researchers from Israel and the US report that they have characterized chromosomal abnormalities in different colorectal cancer stages and identified alterations associated with poor outcomes.

Both the project and the service are designed to offer cancer patients detailed information about their tumor at a timescale that can help their physicians tailor treatments. However, some experts say the results will not benefit many patients today.

Short Reads: Feb 3, 2009

Premium

Broad Institute, Expression Analysis, Helicos BioSciences, University of Texas at Austin, Applied Biosystems, University of Georgia, ABRF, Genomatix, Illumina, Mondobiotech, 23andMe, Kapa Biosystems

Pages

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.